Ubiquitin high-affinity cyclic peptides and methods of using the same
JP2025524355A5Pending Publication Date: 2026-06-15TECHNION RES & DEV FOUND LTD +1
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024572138
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-06
- Filing Date
- 2023-06-06
- Publication Date
- 2026-06-15
AI Technical Summary
Technical Problem
Developing specific cyclic peptides that can interact with Lys63-linked ubiquitin chains is challenging due to their open structure and distinct conformations, making it difficult to interfere with biological pathways such as DNA damage repair.
Method used
Cyclic peptides with nanomolar affinity for Lys63-linked ubiquitin chains are developed using the RaPID method, capable of binding to these chains and inhibiting DNA repair in cancer cells, inducing cell cycle arrest or apoptosis.
Benefits of technology
The cyclic peptides effectively target Lys63-linked ubiquitin chains, providing a therapeutic approach for treating Lys63Ub-related diseases like cancer by inhibiting DNA repair and inducing apoptosis in cancer cells.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides a cyclic peptide and a method of using the cyclic peptide for, among other things, ameliorating or treating K63Ub-related diseases in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art